ZA9810332B - Aminothiazone inhibitors of cyclin dependent kinases. - Google Patents

Aminothiazone inhibitors of cyclin dependent kinases.

Info

Publication number
ZA9810332B
ZA9810332B ZA9810332A ZA9810332A ZA9810332B ZA 9810332 B ZA9810332 B ZA 9810332B ZA 9810332 A ZA9810332 A ZA 9810332A ZA 9810332 A ZA9810332 A ZA 9810332A ZA 9810332 B ZA9810332 B ZA 9810332B
Authority
ZA
South Africa
Prior art keywords
aminothiazone
inhibitors
cyclin dependent
dependent kinases
kinases
Prior art date
Application number
ZA9810332A
Other languages
English (en)
Inventor
Kyoung Soon Kim
S David Kimball
Michael A Poss
Raj N Misra
Zhen-Wei Cai
David B Rawlins
Kevin R Webster
John T Hunt
Wen-Ching Han
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of ZA9810332B publication Critical patent/ZA9810332B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/54—Nitrogen and either oxygen or sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
ZA9810332A 1997-11-12 1998-11-11 Aminothiazone inhibitors of cyclin dependent kinases. ZA9810332B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US6519597P 1997-11-12 1997-11-12

Publications (1)

Publication Number Publication Date
ZA9810332B true ZA9810332B (en) 2000-05-11

Family

ID=22060972

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9810332A ZA9810332B (en) 1997-11-12 1998-11-11 Aminothiazone inhibitors of cyclin dependent kinases.

Country Status (32)

Country Link
US (1) US6040321A (xx)
EP (1) EP1042307B1 (xx)
JP (1) JP4344084B2 (xx)
KR (2) KR100454426B1 (xx)
CN (1) CN1160343C (xx)
AR (1) AR017182A1 (xx)
AT (1) ATE374771T1 (xx)
AU (1) AU730607B2 (xx)
BR (1) BR9814124A (xx)
CA (1) CA2309551C (xx)
CO (1) CO4990957A1 (xx)
CY (1) CY1107509T1 (xx)
CZ (1) CZ297907B6 (xx)
DE (1) DE69838515T2 (xx)
DK (1) DK1042307T3 (xx)
EG (1) EG24028A (xx)
ES (1) ES2296347T3 (xx)
HU (1) HUP0004559A3 (xx)
ID (1) ID23983A (xx)
IL (1) IL135589A (xx)
MY (1) MY120779A (xx)
NO (1) NO316773B1 (xx)
NZ (1) NZ503828A (xx)
PE (1) PE131699A1 (xx)
PL (1) PL204642B1 (xx)
PT (1) PT1042307E (xx)
RU (1) RU2211839C2 (xx)
TR (1) TR200001344T2 (xx)
TW (1) TW593292B (xx)
UY (1) UY25239A1 (xx)
WO (1) WO1999024416A1 (xx)
ZA (1) ZA9810332B (xx)

Families Citing this family (105)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6262096B1 (en) 1997-11-12 2001-07-17 Bristol-Myers Squibb Company Aminothiazole inhibitors of cyclin dependent kinases
US6214852B1 (en) * 1998-10-21 2001-04-10 Bristol-Myers Squibb Company N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases
US6414156B2 (en) 1998-10-21 2002-07-02 Bristol-Myers Squibb Company Process for preparing azacycloalkanoylaminothiazoles
US6337338B1 (en) * 1998-12-15 2002-01-08 Telik, Inc. Heteroaryl-aryl ureas as IGF-1 receptor antagonists
CA2352326A1 (en) * 1998-12-22 2000-06-29 Warner-Lambert Company Combination chemotherapy
US20040171632A1 (en) * 1998-12-22 2004-09-02 Gowan Richard Carleton Combination chemotherapy
WO2000061552A1 (fr) * 1999-04-07 2000-10-19 Santen Pharmaceutical Co., Ltd. DERIVE D'UREE N-SUBSTITUE-N'-SUBSTITUE, ET SON UTILISATION COMME INHIBITEUR DE LA PRODUCTION DE TNF-$g(a)
ES2391550T3 (es) 1999-04-15 2012-11-27 Bristol-Myers Squibb Company Inhibidores cíclicos de la proteína tirosina quinasa
US7125875B2 (en) 1999-04-15 2006-10-24 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
UA71971C2 (en) 1999-06-04 2005-01-17 Agoron Pharmaceuticals Inc Diaminothiazoles, composition based thereon, a method for modulation of protein kinases activity, a method for the treatment of diseases mediated by protein kinases
AU6314900A (en) 1999-07-26 2001-02-13 Banyu Pharmaceutical Co., Ltd. Biarylurea derivatives
US6114365A (en) * 1999-08-12 2000-09-05 Pharmacia & Upjohn S.P.A. Arylmethyl-carbonylamino-thiazole derivatives, process for their preparation, and their use as antitumor agents
US6392053B2 (en) 1999-12-15 2002-05-21 Bristol-Myers Squibb Company Process for preparing arylacetylaminothiazoles
MY125768A (en) * 1999-12-15 2006-08-30 Bristol Myers Squibb Co N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases
US6515004B1 (en) 1999-12-15 2003-02-04 Bristol-Myers Squibb Company N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases
YU54202A (sh) 2000-01-18 2006-01-16 Agouron Pharmaceuticals Inc. Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije
HN2001000008A (es) 2000-01-21 2003-12-11 Inc Agouron Pharmaceuticals Compuesto de amida y composiciones farmaceuticas para inhibir proteinquinasas, y su modo de empleo
AU2001230026A1 (en) * 2000-02-04 2001-08-14 Novo-Nordisk A/S 2,4-diaminothiazole derivatives
IT1317826B1 (it) * 2000-02-11 2003-07-15 Dompe Spa Ammidi, utili nell'inibizione della chemiotassi dei neutrofiliindotta da il-8.
WO2001079198A1 (en) 2000-04-18 2001-10-25 Agouron Pharmaceuticals, Inc. Pyrazoles for inhibiting protein kinase
US6534531B2 (en) * 2000-04-27 2003-03-18 Bristol-Myers Squibb Company Methods for preventing and treating alopecia induced by chemotherapy or radiotherapy
AU2001264376A1 (en) * 2000-06-15 2001-12-24 Chaconne Nsi Co., Ltd. Urea derivative useful as an anti-cancer agent and process for preparing same
GEP20043367B (en) * 2000-07-26 2004-06-10 Bristol Myers Squibb Co N-[5-[[[5-Alkyl-2-Oxazolyl]Methyl]Thio]-2-Thiazolyl Carboxamide Inhibitors of Cyclin Dependent Kinases
WO2002012250A2 (en) 2000-08-09 2002-02-14 Agouron Pharmaceuticals, Inc. Pyrazole-thiazole compounds, pharmaceutical compositions containing them, and methods of their use for inhibiting cyclin-dependent kinases
US20020173507A1 (en) * 2000-08-15 2002-11-21 Vincent Santora Urea compounds and methods of uses
US6645990B2 (en) 2000-08-15 2003-11-11 Amgen Inc. Thiazolyl urea compounds and methods of uses
EP1347971B1 (en) 2000-12-21 2006-03-01 Bristol-Myers Squibb Company Thiazolyl inhibitors of tec family tyrosine kinases
US6756374B2 (en) 2001-01-22 2004-06-29 Hoffmann-La Roche Inc. Diaminothiazoles having antiproliferative activity
EE05301B1 (et) 2001-01-25 2010-06-15 Bristol-Myers Squibb Company Meetod epotilooni analooge sisaldavate ravimvormide valmistamiseks ning nende kasutamine ravimi valmistamiseks
SI1372650T1 (sl) * 2001-03-19 2009-04-30 Novartis Ag Kombinacije, ki obsegajo antidiaroično sredstvo in epotilon ali epotilonski derivat
ATE315555T1 (de) 2001-05-11 2006-02-15 Pfizer Prod Inc Thiazolderivate und ihre verwendung als cdk- inhibitoren
EP1721609A3 (en) * 2001-05-16 2007-01-31 GPC Biotech AG Pyridylpyrimidine derivatives as effective compounds against prion diseases
JP2004535411A (ja) 2001-05-25 2004-11-25 ブリストルーマイヤーズ スクイブ カンパニー マトリックスメタロプロテナーゼ及び／またはＴＮＦ−α転換酵素（ＴＡＣＥ）の阻害剤としてのヒダントイン及び関連複素環化合物
HN2002000156A (es) 2001-07-06 2003-11-27 Inc Agouron Pharmaceuticals Derivados de benzamida tiazol y composiciones farmaceuticas para inhibir la proliferacion de celulas y metodos para su utilización.
PL367938A1 (en) * 2001-07-19 2005-03-07 Pharmacia Italia S.P.A. Phenylacetamido-thiazole derivatives, process for their preparation and their use as antitumor agents
PL368035A1 (en) * 2001-08-31 2005-03-21 Bristol-Myers Squibb Company Compositions and methods for the treatment of cancer
US7405234B2 (en) * 2002-05-17 2008-07-29 Bristol-Myers Squibb Company Bicyclic modulators of androgen receptor function
TW200401638A (en) * 2002-06-20 2004-02-01 Bristol Myers Squibb Co Heterocyclic inhibitors of kinases
EP2471533A1 (en) 2002-06-27 2012-07-04 Novo Nordisk A/S Aryl carbonyl derivatives as therapeutic agents
MXPA05002570A (es) * 2002-09-04 2005-09-08 Schering Corp Pirazolopirimidinas como inhibidores de cinasa dependientes de ciclina.
EP1545533A1 (en) * 2002-09-04 2005-06-29 Schering Corporation Pyrazolopyrimidines as cyclin dependent kinase inhibitors
US7161003B1 (en) 2002-09-04 2007-01-09 Schering Corporation Pyrazolopyrimidines as cyclin dependent kinase inhibitors
JP2006501260A (ja) * 2002-09-04 2006-01-12 シェーリング　コーポレイション サイクリン依存性キナーゼインヒビターとしてのピラゾロピリミジン
US7205308B2 (en) * 2002-09-04 2007-04-17 Schering Corporation Trisubstituted 7-aminopyrazolopyrimidines as cyclin dependent kinase inhibitors
US7119200B2 (en) * 2002-09-04 2006-10-10 Schering Corporation Pyrazolopyrimidines as cyclin dependent kinase inhibitors
US7196078B2 (en) * 2002-09-04 2007-03-27 Schering Corpoartion Trisubstituted and tetrasubstituted pyrazolopyrimidines as cyclin dependent kinase inhibitors
US7067661B2 (en) * 2002-09-04 2006-06-27 Schering Corporation Pyrazolopyrimidines as cyclin dependent kinase inhibitors
ATE374768T1 (de) 2002-10-03 2007-10-15 Hoffmann La Roche Indole-3-carbonsaüreamide als glucokinase (gk) aktivatoren
CN1703408A (zh) * 2002-10-03 2005-11-30 诺瓦提斯公司 作为葡糖激酶激活剂、可用于治疗ⅱ型糖尿病的取代的(噻唑－2－基)酰胺或磺酰胺
RU2005115842A (ru) * 2002-10-24 2006-03-10 Мерк Патент ГмбХ (DE) Производные метиленмочевины
WO2004045518A2 (en) * 2002-11-15 2004-06-03 Bristol-Myers Squibb Company Open chain prolyl urea-related modulators of androgen receptor function
US20070105114A1 (en) * 2003-07-29 2007-05-10 Martha Li Biomarkers of cyclin-dependent kinase modulation
US6949895B2 (en) * 2003-09-03 2005-09-27 Axcelis Technologies, Inc. Unipolar electrostatic quadrupole lens and switching methods for charged beam transport
US7256208B2 (en) * 2003-11-13 2007-08-14 Bristol-Myers Squibb Company Monocyclic N-Aryl hydantoin modulators of androgen receptor function
US20050171182A1 (en) * 2003-12-11 2005-08-04 Roger Briesewitz Methods and compositions for use in the treatment of mutant receptor tyrosine kinase driven cellular proliferative diseases
CA2551324C (en) 2004-01-06 2012-11-27 Novo Nordisk A/S Heteroaryl-ureas and their use as glucokinase activators
WO2005072731A1 (en) * 2004-01-29 2005-08-11 X-Ceptor Therapeutics, Inc. 3-phenyl-n- ((1, 3, 4) thiadiazol-2-yl) -acrylamide derivatives and related compounds as modulators of estrogen-related receptors for the treatment of e.g. cancer, rheumatoid arthritis or neurological disorders
ES2791303T3 (es) * 2004-01-30 2020-11-03 Vertex Pharma Compuesto intermedio de moduladores de transportadores de casete de unión a ATP
US7977322B2 (en) 2004-08-20 2011-07-12 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
US7820702B2 (en) 2004-02-04 2010-10-26 Bristol-Myers Squibb Company Sulfonylpyrrolidine modulators of androgen receptor function and method
US20050182105A1 (en) * 2004-02-04 2005-08-18 Nirschl Alexandra A. Method of using 3-cyano-4-arylpyridine derivatives as modulators of androgen receptor function
EP1568368A1 (en) * 2004-02-26 2005-08-31 Schering Aktiengesellschaft Pharmaceutical combination comprising a CDK inhibitor and a VEGF receptor inhibitor
US7378426B2 (en) 2004-03-01 2008-05-27 Bristol-Myers Squibb Company Fused heterotricyclic compounds as inhibitors of 17β-hydroxysteroid dehydrogenase 3
US7696241B2 (en) * 2004-03-04 2010-04-13 Bristol-Myers Squibb Company Bicyclic compounds as modulators of androgen receptor function and method
US7625923B2 (en) 2004-03-04 2009-12-01 Bristol-Myers Squibb Company Bicyclic modulators of androgen receptor function
US7388027B2 (en) * 2004-03-04 2008-06-17 Bristol-Myers Squibb Company Bicyclic compounds as modulators of androgen receptor function and method
US7211576B2 (en) 2004-04-20 2007-05-01 Hoffmann-La Roche Inc. Diaminothiazoles
PL1817013T3 (pl) 2004-11-18 2009-01-30 Bristol Myers Squibb Co Dojelitowa powlekana peletka zawierająca Ixabepilone
US20100105745A1 (en) * 2005-01-04 2010-04-29 Toshinari Minamoto Suppression of cancer and method for evaluating anticancer agent based on the effect of inhibiting gsk3 beta
EP1845094A4 (en) * 2005-01-04 2009-12-16 Univ Kanazawa Nat Univ Corp METHOD OF TUMOR SUPPRESSION AND EVALUATION OF ANTICANCER AGENT BASED ON THE INHIBITORY EFFECT OF GSK3 BETA
ATE547396T1 (de) 2005-07-08 2012-03-15 Novo Nordisk As Dicycloalkylcarbamoyl-harnstoffe als glucokinase- aktivatoren
US7884210B2 (en) * 2005-07-14 2011-02-08 Novo Nordisk A/S Ureido-thiazole glucokinase activators
CN101365700A (zh) * 2005-11-15 2009-02-11 沃泰克斯药物股份有限公司 可用作激酶抑制剂的氮杂吲唑
US7592461B2 (en) 2005-12-21 2009-09-22 Bristol-Myers Squibb Company Indane modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
US7888504B2 (en) * 2006-07-06 2011-02-15 Bristol-Myers Squibb Company Glucokinase activators and methods of using same
WO2008049856A2 (en) * 2006-10-25 2008-05-02 Ingenium Pharmaceuticals Gmbh Methods of treating pain using cdk inhibitors
US8017749B2 (en) 2006-12-04 2011-09-13 The Board Of Trustees Of The University Of Illinois Compositions and methods to treat cancer with cupredoxins and CpG rich DNA
AU2010343102B2 (en) 2009-12-29 2016-03-24 Dana-Farber Cancer Institute, Inc. Type II Raf kinase inhibitors
MX2012013031A (es) 2010-05-12 2012-12-17 Univ Vanderbilt Potenciadores alostericos mglur4 de sulfona heterociclica, composiciones y metodos para tratar disfuncion neurologica.
WO2011159726A2 (en) 2010-06-14 2011-12-22 The Scripps Research Institute Reprogramming of cells to a new fate
CN103269593A (zh) * 2010-11-01 2013-08-28 罗马克实验室有限公司 烷基亚磺酰基取代的噻唑化物化合物
AU2012207142B2 (en) 2011-01-20 2017-04-27 Board Of Regents, The University Of Texas System MRI markers, delivery and extraction systems, and methods of manufacture and use thereof
CN102863474A (zh) 2011-07-09 2013-01-09 陈小平 一类治疗细胞增殖性疾病的铂化合物、其制备方法和应用
CN102993239A (zh) 2011-09-19 2013-03-27 陈小平 离去基团含氨基或烷胺基的丁二酸衍生物的铂类化合物
US8940742B2 (en) * 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2014075391A1 (zh) 2012-11-17 2014-05-22 北京市丰硕维康技术开发有限责任公司 离去基团是含氨基或烷氨基的丙二酸衍生物的铂类化合物
AU2014236719B2 (en) 2013-03-15 2018-06-21 The California Institute For Biomedical Research Compounds and methods for inducing chondrogenesis
EP3052485B1 (en) 2013-10-04 2021-07-28 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US9751888B2 (en) 2013-10-04 2017-09-05 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EP4066834A1 (en) 2014-03-19 2022-10-05 Infinity Pharmaceuticals, Inc. Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
GB201409471D0 (en) 2014-05-28 2014-07-09 Euro Celtique Sa Pharmaceutical composition
US9708348B2 (en) 2014-10-03 2017-07-18 Infinity Pharmaceuticals, Inc. Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof
EP3273966B1 (en) 2015-03-27 2023-05-03 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
AU2016319125B2 (en) 2015-09-09 2021-04-08 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
EP3350183A1 (en) 2015-09-14 2018-07-25 Infinity Pharmaceuticals, Inc. Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same
US10759806B2 (en) 2016-03-17 2020-09-01 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors
CA3018026A1 (en) * 2016-04-06 2017-10-12 Innovative Molecules Gmbh Aminothiazole derivatives useful as antiviral agents
US10919914B2 (en) 2016-06-08 2021-02-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2018068832A1 (en) 2016-10-11 2018-04-19 Euro-Celtique S.A. Hodgkin lymphoma therapy
GB201709406D0 (en) 2017-06-13 2017-07-26 Euro-Cletique S A Compounds for treating TNBC
GB201709405D0 (en) 2017-06-13 2017-07-26 Euro Celtique Sa Compounds for treating ovarian cancer
GB201709402D0 (en) 2017-06-13 2017-07-26 Euro Celtique Sa Compounds for treating t-pll
MA50609B1 (fr) * 2017-10-05 2023-03-31 Innovative Molecules Gmbh Énantiomères de thiazoles substitués utilisés comme composés antiviraux
CN112040945A (zh) 2018-06-12 2020-12-04 Vtv治疗有限责任公司 葡萄糖激酶激活剂与胰岛素或胰岛素类似物组合的治疗用途
WO2022079290A2 (en) * 2020-10-16 2022-04-21 Cemm - Forschungszentrum Für Molekulare Medizin Gmbh Cullin ring ubiquitin ligase compounds and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1088049A (en) * 1975-06-03 1980-10-21 Takashi Masugi 3-substituted-7-substituted alkanamido-3-cephem-4- carboxylic acid compounds and processes for preparation thereof
NO831160L (no) * 1982-04-08 1983-10-10 Erba Farmitalia Fremstilling av substituerte penem-derivater
JPS6339868A (ja) * 1986-08-04 1988-02-20 Otsuka Pharmaceut Factory Inc ジ低級アルキルフエノ−ル誘導体
DE4119756A1 (de) * 1991-06-15 1992-12-17 Basf Ag Aminoalkylsubstituierte 5-mercaptothiazole, ihre herstellung und verwendung
JPH0859669A (ja) * 1994-06-13 1996-03-05 Takeda Chem Ind Ltd セフェム化合物、その製造法及び剤

Also Published As

Publication number Publication date
CA2309551C (en) 2006-03-28
KR20010031896A (ko) 2001-04-16
PL340540A1 (en) 2001-02-12
EG24028A (en) 2008-03-26
PL204642B1 (pl) 2010-01-29
ES2296347T3 (es) 2008-04-16
CA2309551A1 (en) 1999-05-20
HUP0004559A3 (en) 2002-05-28
UY25239A1 (es) 2000-12-29
CN1278806A (zh) 2001-01-03
TR200001344T2 (tr) 2000-09-21
EP1042307A4 (en) 2003-01-29
MY120779A (en) 2005-11-30
CO4990957A1 (es) 2000-12-26
BR9814124A (pt) 2000-10-03
KR20030036862A (ko) 2003-05-09
ID23983A (id) 2000-06-14
ATE374771T1 (de) 2007-10-15
AR017182A1 (es) 2001-08-22
PE131699A1 (es) 2000-03-08
DE69838515D1 (de) 2007-11-15
HUP0004559A1 (hu) 2002-04-29
EP1042307A1 (en) 2000-10-11
US6040321A (en) 2000-03-21
JP4344084B2 (ja) 2009-10-14
DK1042307T3 (da) 2008-01-28
NO20002153L (no) 2000-05-11
DE69838515T2 (de) 2008-07-03
IL135589A0 (en) 2001-05-20
JP2001522842A (ja) 2001-11-20
NO316773B1 (no) 2004-05-03
NZ503828A (en) 2003-03-28
KR100454426B1 (ko) 2004-10-26
EP1042307B1 (en) 2007-10-03
AU1295599A (en) 1999-05-31
AU730607B2 (en) 2001-03-08
CN1160343C (zh) 2004-08-04
TW593292B (en) 2004-06-21
CZ20001744A3 (en) 2001-05-16
CZ297907B6 (cs) 2007-04-25
WO1999024416A1 (en) 1999-05-20
PT1042307E (pt) 2007-11-15
CY1107509T1 (el) 2013-03-13
IL135589A (en) 2004-06-20
RU2211839C2 (ru) 2003-09-10
NO20002153D0 (no) 2000-04-27

Similar Documents

Publication Publication Date Title
ZA9810332B (en) Aminothiazone inhibitors of cyclin dependent kinases.
PL340727A1 (en) Benzothiazolic inhibitors of proteinous thyrosinic kinase
HK1041599A1 (en) Pyrrolotriazine inhibitors of kinases
AU8760798A (en) Irreversible inhibitors of tyrosine kinases
ZA986729B (en) Irreversible inhibitors of tyrosine kinases
PL337697A1 (en) Farnesil-proteinous transferase inhibitors
EP1087951A4 (en) CARBON SUBSTITUTED AMINOTHIAZOLE, CYCLINE DEPENDENT KINASE INHIBITORS
HK1049662A1 (zh) 細胞周期蛋白依賴激酶氨基噻唑抑制劑
PL322584A1 (en) Inhibitors of proteinous kinase c
PL326754A1 (en) Inhibitors of proteinous kinase c
AU1116497A (en) Inhibitors of cyclin-dependent kinases
HK1039326A1 (zh) 4氨基吡咯並嘧啶作為激酶抑制劑
PL334846A1 (en) Sulphamidic inhibitors of metaloproteases
AU1536799A (en) Bishydroxyureas as inhibitors of the 5-lipoxygenase
GB9809869D0 (en) Inhibition of protein kinases
HK1049661A1 (en) N-Ä5-ÄÄÄ5-alkyl-2-oxazolylÜmethylÜthioÜ-2-thiazolyn carboxamide inhibitors of cyclin dependent kinases.
HU0900792D0 (en) Use of renin-angiotensin inhibitors
AU6882598A (en) Protein kinase inhibitor
AU4685799A (en) Telomerase inhibitors
AU2445997A (en) Telomerase inhibitors
AU9526198A (en) Method for inhibiting eukaryotic protein kinases
AU9526298A (en) Method for inhibiting eukaryotic protein kinases
GB9714603D0 (en) Cyclin dependent kinase inhibitors
GB9806743D0 (en) Cyclin dependent kinase inhibitors
AU7427098A (en) Inhibitors of g-protein-beta/gamma subunit function